OBJECTIVE: To investigate the relationship between the polymorphisms of the b b 3 ± AR (Trp64Arg), UCP1 (A?G) and LPL (HindIII and PvuII) loci and the metabolic complications associated with obesity in a Turkish population. SUBJECTS: 271 unrelated individuals of Turkish origin including obese (body mass index, BMIb b30 kga am 2 ) and lean (BMI 25 kga am 2 ) subjects. MEASUREMENTS: Anthropometric (weight, height and blood pressure) and metabolic measurements (plasma levels of glucose, cholesterol and triglycerides), and determination of b b 3 ± AR, UCP1 and LPL genotypes by polymerase chain reaction followed by enzymatic digestion. RESULTS: The distributions of genotypes for each candidate gene (b b 3 ± AR, UCP1 and LPL) were similar between the obese and the lean subjects. The Arg 64 allele of the b b 3 ± AR gene was absent from massively obese men. GG carriers of the A?G variant of the UCP1 gene showed BMI-associated increases of cholesterol levels which were more marked than both AA (P 0.027) and AG (P 0.039) carriers. Obese P carriers of the LPL PvuII variant had signi®cantly higher levels of glucose than non-carriers (P 0.011), whereas obese P P carriers did not have signi®cantly different levels of triglycerides than non-carriers (P 0.087). Moreover, carriers of both alleles (G&P ) had higher levels of glucose than non-carriers (P 0.048), but did not have signi®cantly different levels of triglycerides than non-carriers (P 0.125). However, the BMI-associated increase of triglycerides of P&G carriers was signi®cantly more marked than that of P carriers (P 0.0085). CONCLUSION: Our data support the idea that alleles of speci®c genes (UCP1, LPL and b b 3 ± AR) might play a role in the development of certain metabolic complications of obesity and might have additive effects when combined with each other (as in the case of UCP1 and LPL).
Introduction
Obesity is associated with several metabolic complications such as hypertension, hypertriglyceridaemia, hyperglycaemia and insulin resistance, thus constituting a major risk factor for ill health, leading to cardiovascular diseases and diabetes. 1 Metabolic disorders in human beings are complex multifactorial traits that are in¯uenced by numerous factors. In addition to the leptin encoded by the OB gene, 2 the products of several other genes have been shown to be involved in the metabolic network that controls body weight. The genes encoding the b 3 adrenoreceptor (b 3 ± AR) and the uncoupling protein 1 (UCP1) are involved in thermogenesis. Associations of these genes with obesity have been reported in various human populations. The Trp64Arg polymorphism identi®ed in the b 3 ± AR gene has been associated with a tendency to lower resting metabolic rate in Pima Indians 3 and with an increased capacity to gain weight in French patients with morbid obesity. 4 In Japanese and Finns, this mutation has been found to be associated with obesity and hyperinsulinaemiaainsulin resistance. 5, 6 Several other studies have con®rmed these initial reports while others have not (reviewed in Strosberg. 7 The A?G polymorphism of he UCP1 gene was also studied in morbidly obese French patients. In this population, an association with high weight gain during adult life was observed and an additive effect of both Trp64Arg and A?G polymorphisms on weight gain was also reported. 8 Nevertheless, none of these genes appear to play a major role in the development of obesity.
Lipoprotein lipase (LPL) is a key enzyme for the hydrolysis of triglyceride-rich lipoproteins, and its activity is positively correlated with plasma cholesterol levels. Various restriction fragment length polymorphisms (RFLP) have been identi®ed at the LPL locus. The HindIII polymorphism at the LPL gene has been found to be associated with hypertriglyceridaemia, decreased HDL-cholesterol levels, increased apo B levels and coronary heart disease. 1 Another variant of the LPL gene, the PvuII polymorphism, has been associated with variations in plasma triglyceride concentration 9 and coronary artery disease severity. 10 The products of the LPL, UCP1 and b 3 ± AR genes are metabolically closely related. Sympathetic stimulation of the adipocyte acts in part upon the b 3 ± AR, both in mediating the lipolysis activation and in the utilisation of intracellular fatty acids in the uncoupled respiration of the thermogenic mitochondria that depends on the uncoupling proteins. 11 LPL catalyses the incorporation of fatty acids into the adipocyte, regulating both availability for thermogenesis and the ef®ciency of storage as fat.
Numerous data demonstrate a consistent relationship between the presence of obesity and an increased prevalence of coronary heart disease risk factors such as hypertension and hyperlipidaemia. 12 A recent survey from the Turkish Heart Study indicates that the Turkish population exhibits a high incidence of coronary disease, estimated at 37% of deaths by the Turkish Ministry of Health. 13 These data and the different genetic background of this population compared with other Caucasian populations made the Turkish an interesting population for studies on the relationship between polymorphic forms of candidate genes and metabolic complications of obesity.
The aim of this study was to investigate the relationship between the polymorphisms of the b 3 ± AR, UCP1 and LPL gene loci and the obese phenotype in a Turkish population. We tested the hypothesis that several candidate genes, either individually or combined, may modify metabolic risk variables in obesity, such as arterial blood pressure, and plasma levels of glucose, triglycerides and cholesterol. Our data support the idea that alleles of speci®c genes might play a role in the development of metabolic complications of obesity and have a possible additive effect when combined with each other.
Methods

Subjects
The subjects of the present study were recruited at the Department of Endocrinology, Gulha Ène School of Medicine, Ankara, Turkey. The whole sample comprised 271 unrelated individuals (186 men and 85 women) of Turkish origin and born in different regions of the country. From this population we constituted two groups: 94 (77 males and 17 females) lean subjects (body mass index, BMI 25 kgam 2 ) and 146 (83 males and 63 females) obese subjects (BMI b 30 kgam 2 ). The mean age for each group was 30AE 1 and 35 AE 1 y, respectively. The control (lean) subjects were healthy and had no history of hyperlipidaemia, diabetes or hypertension. In the obese group, diabetic subjects (n 40, 27.4% of the obese subjects) were de®ned according to the oral glucose tolerance test.
14 Diabetic subjects as well as subjects who were not in fasting conditions when blood was drawn (n 21, 9.3% of the population) were excluded from the genotype ± phenotype relationship study.
Anthropometric and metabolic measurements
Weight and height measurements were recorded. BMI was calculated as the body weight (kg) divided by the square of the height (m 2 ). Systolic and diastolic blood pressure were measured after 10 min rest in the supine position.
Blood samples were drawn after an overnight fast and analysed immediately. Blood glucose was measured by an enzymatic colourimetric method using glucose oxidase 15, 16 on an RA ± 1000 autoanalyzer. Total cholesterol was measured by the CHOD-PAP method using a Menagent Cholesterol-HF kit (Menarini Diagnostics, Florence, Italy). 17 Triglycerides were measured by an enzymatic colourimetric method using a Menagent Triglycerides kit (Menarini Diagnostics, Florence, Italy). 18, 19 
DNA analysis
Peripheral venous blood (10 ml) was collected in tubes containing EDTA and kept frozen at À20 C until processing. Genomic DNA was extracted from white blood cells by standard methods after digestion with proteinase K and extraction with phenolachloroform. 20 The detection of the four polymorphisms studied here was carried out by PCR ampli®cation of speci®c fragments and subsequent digestion with restriction endonucleases. b 3 ± AR Trp64Arg polymorphism. PCR ampli®cation of the region containing the Trp64Arg b 3 ± AR polymorphism was carried out. Primers were: forward primer, 5
H CCA GTG GGC TGC CAG GGG 3 H ; and reverse primer, 5
H GCC AGT GGC GCC CAA CGG 3 H , as previously described. 3 The 248 bp ampli®ed product was digested with BstNI (New England Biolabs, Beverly, MA, USA). The presence of two restriction sites (Trp 64 allele) resulted in fragments of 97, 61 and 64pb, and the loss of one restriction site (Arg 64 allele) resulted in fragments of 158 and 64pb. H CTC CCT AGA ACA GAA GAT C 3 H . 22 After digestion with HindIII (GibcoBRL, MA, USA), the H allele resulted in two fragments of 700 and 600 bp, whereas HÀ allele retained the size of 1.3 kb.
LPL PvuII polymorphism. For ampli®cation of the sequence around the PvuII site the primers were 5 H TAG AGG TTG AGG CAC CTG TGC 3 H and 5 H GTG GGT GAA TCA CCT GAG GTC 3
H . 22 The 858 bp ampli®ed fragment was digested with PvuII (GibcoBRL, MA, USA). The presence of the PvuII site (P allele) yielded fragments of 592 and 266 bp.
Statistical analysis
Statistical analysis was performed using the chisquare test for comparisons of genotype frequencies. A test of linear trend was done with the b 3 -AR Trp64Arg polymorphism. Allele frequencies for each polymorphic site were estimated by the genecounting method. The distribution of single diallelic RFLPs was tested for Hardy ± Weinberg equilibrium with a chi-square test. For comparison between groups Student's t-test, one-way ANOVA and multiple linear regression analysis were performed. All statistics were performed using the BMDP and SPSS-X packages on a VAX8820 computer.
Results
Metabolic parameters in lean and obese subjects
Two groups of individuals were studied Ð lean (BMI 25) and obese (BMI b 30). Table 1 presents clinical characteristics for both study groups. Not surprisingly, subjects with BMI values over 30 have signi®cantly higher glucose, cholesterol and triglyceride concentrations than lean subjects.
Allele and genotype frequencies
Allele frequencies for all polymorphisms were in Hardy ± Weinberg equilibrium in both the lean (Arg 64 allele frequency: 0.11; G allele frequency: 0.30; H allele frequency: 0.78; P allele frequency: 0.59) and obese (Arg 64 ellele frequency: 0.07; G ellele frequency: 0.31; H allele frequency: 0.75; P allele frequency: 0.57) groups. In general, we found that the distributions of genotypes for each candidate gene (b 3 ± AR, UCP1 and LPL) were similar between the obese patients and the lean subjects (Table 2) . However, it can be seen that the percentage of men carrying the Arg 64 allele (both in heterozygote and homozygote form) decreases as obesity degree increases (Figure 1) , and reaches the zero value for morbid obesity (test of linear trend: chi-square 5.78, P 0.016). Interestingly, the percentage of women carrying the Arg 64 allele does not change in the different obesity groups (test of linear trend: chisquare 0.80, P 0.37). Genetic variants and metabolic disorders in obesity AM Proenza et al Genotype ± phenotype relationship in lean and obese subjects
We observed (Figure 2 ) that there was a liner, positive, relationship between plasma levels of cholesterol and BMI values for each of the three UCP1 genotype groups Ð AA (P 0.0001), AG (P 0.0045) and GG (P 0.0000). Moreover, comparisons between lines indicate differences between GG subjects and both AA (P 0.027) and AG (P 0.039) subjects. Thus, carriers of the G allele in homozygote form showed signi®cantly more marked (slop 5.6) increases of cholesterol levels associated with the degree of obesity than both non-carriers (slope 2.0) and carriers of the mutated allele in heterozygote form (slope 1.9). There were no differences between AA and AG lines. Comparisons between groups (ttest) indicated differences in the levels of cholesterol between obese AA carriers and GG carriers that did not reach statistical signi®cance (P 0.22).
In the obese group, carriers of the LPL PvuII P allele (Figure 3 ), in both homozygote and heterozygote form, had higher levels of glucose than noncarriers (P 0.066 and P 0.011, respectively). There was a similar trend for triglyceride levels (Figure 4) , although it was not signi®cant (P 0.087 and P 0.166, respectively).
Obese subjects carrying both the P and G alleles ( Figure 5 had signi®cantly higher levels of glucose than non-carriers (P 0.048). No signi®cant 
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AM Proenza et al difference between other genotype groups was found, thus indicating that the magnitude of the increase of the levels of glucose in obese subjects was associated with the presence of both alleles. Carriers of both alleles (P & G) also tended to have higher levels of triglycerides ( Figure 6 ) than non-carriers, although this difference did not reach statistical signi®cance (P 0.125). Multiple regression analysis indicated that there was a linear relationship between levels of triglycerides and BMI in subjects carrying the P allele (slope 2.4, P 0.018) and also in subjects carrying the G & P alleles (slope 7.6, P 0.0000), and that both lines signi®cantly differed (P 0.0085).
No signi®cant difference in the levels of glucose, cholesterol and triglycerides between genotype groups was found in lean subjects.
Discussion
To the best of our knowledge, the present data provide the ®rst report of obesity candidate gene analysis in Turkey. This study suggests that alleles of speci®c genes, both individually and in combination, may intervene in the worsening of the metabolic complications of obesity.
A problem frequently encountered in association studies is the dif®culty in selecting appropriate controls. This explains the distortion of the results for a speci®c genetic marker in many case ± control studies. In the present paper, both obese and controls were of Turkish ancestry and came from the same geographic regions, which reduces biases associated with differences in ethnic or genetic backgrounds. In addition, the genetic homogeneity of the Turkish population has previously been reported. 23 The genotype frequencies of the b 3 ± AR, UCP1 and LPL gene polymorphisms found in our sample are similar to those previously reported in other Caucasian populations 1, 4, 22, 24, 25 and do not differ when lean and obese groups are compared. These genes taken separately do not appear to constitute major determinants for the development of obesity.
Interestingly, the Arg 64 allele of b 3 ± AR gene is absent in massively obese men. Cle Âment et al 4 indicated that the Trp64Arg mutation may have a deleterious effect because in their study, among 185 patients with morbid obesity, 14 were hetrozygous and none were homozygous. Recent review on Trp64Arg polymorphism including over 10,000 patients suggests a decreased life expectancy of Arg 64 homozygotes, except in Pima Indians, given the much lower than expected prevalence in the other populations. 7 In the Turkish population, the number of homozygotes is also low (n 3). Moreover, the proportion of Arg64 carriers, both homozygotes and heterozygotes, decreases as BMI increases in men but not in women. Our data contribute to the idea of a possible selective effect of this mutated allele directed to morbidly obese men. Cardiovascular complications of obesity are more common in men than women, and several risk factors, such as hypertension, hyperlipidaemia and glucose intolerance, have been thought to be caused by the increased release of free fatty acids by the portal venous system. b 3 ± AR in visceral fat appears to be responsible for lipolysis and fatty acid release in the portal vein 26 and the rate of this catecholamine-induced mobilisation is higher in men than in women. 27 It could be hypothetically considered that the decrease in the proportion of male carriers of the Arg64 allele could re¯ect the genderspeci®c differences in metabolic and cardiovascular disturbances that accompany obesity. However to support this assumption, further studies are needed in the present or other human populations.
In our population the ratio between women and men is higher in the obese group than in the lean group. In the obese group 44% are women, whereas there are only 18% in the lean group. However, this fact does not affect our results since there are no signi®cant differences in the levels of glucose, cholesterol and triglycerides between men and women in Figure 6 (A) Plasma levels of triglycerides in lean and obese subjects according to the A?G UCP1 and LPL PvuII genotypes. *P`0.05 obese vs lean; (B) Plasma levels of triglycerides in Turkish subjects according to their BMI values. P: y 992.4x; G&P: y À347.6x. *P`0.05 G&Pline vs Pline.
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Actually, to avoid possible false conclusions due to the presence of diabetes, normoglycaemics have been analysed separately. Interestingly, when comparing both subpopulations (diabetics vs normoglycaemics) the distributions of the Trp64Arg b 3 ± AR genotypes are statistically different between groups (w 2 7.8, P 0.0207), the Arg 64 carriers being more represented in the diabetic group. Thus, 8.3% of the nondiabetic subjects are carriers of the Trp64 allele (in heterozygote form only), whereas the percentage is 21.9% in the diabetic group (15.6% of heterozygotes and 6.3% of homozygotes). This would give further support to the proposed involvement of the genetic variants studied in the metabolic complications of obesity. However the limited number of diabetics (n 32) prevents us from reaching more detailed conclusions. Apart from this quotation the diabetic subjects were not considered in the genotype ± phenotype analyses but rather excluded.
Our results indicate that among the polymorphisms studied the A?G variant of the UCP1 gene and the PvuII polymorphism of the LPL gene appear to be the more clearly involved in the metabolic disorders linked to obesity. The presence of the mutant allele G, mainly in its homozygote form, is statistically associated with a higher increase of plasma cholesterol levels, an increase which is signi®cantly higher than that observed in the non-carriers of this allele. Cholesterol is among the risk factors for cardiovascular disease which have been associated with obesity by epidemiological studies. 28 Moreover, changes in body weight have been found to be associated with changes in blood levels of cholesterol. 29, 30 Our study suggests that the intensity of these changes would increase as the presence of UCP1 G allele does.
The association between LPL PvuII P allele and the higher increase of triglyceridemia of obesity found here agrees with that reported by a previous work. 9 This relationship could have a physiological importance since increased triglyceride levels in women have been found to be associated with higher waist-tohip ratio Ð a measure of central adiposity. 31 Moreover, central adiposity strongly correlates with cardiovascular disease. 32 Thus, the P allele would be involved in the metabolic complications of obesity due to its effect on triglyceride and glucose levels.
Our results did not show a signi®cant effect of the H allele on obesity-related metabolic complications (data not shown) in spite of the fact that both alleles (P and H) belong to the same gene. There is a combined effect of the G and P alleles on the obesity-linked increase of the levels of glucose and triglycerides. In addition, our results suggest that when obese subjects are carriers of both G and P alleles he increase of triglyceridaemia is more marked than that produced by P allele alone (see Figure 6) . Thus, the A?G variant, in enhancing the effect of P allele on triglyceride levels, could play a role in obesity-linked lipid disturbances which have been classically restricted to LPL gene polymorphisms.
Genetic predisposition has been hypothesized to be a key factor in the susceptibility of obese individuals to metabolic disorders. 34 Our results reveal that the consequences of body weight increase on he metabolic parameters in our population vary according to the genotype. This fact supports the idea that the genes studies, UCP1, LPL and b 3 ± AR to a lesser extent, could be involved in a susceptibility towards obesity-linked metabolic alterations. It can be noticed that the differences found here between genotype groups, when existing, are always present in the obese group only and not in the lean group, suggesting that these are obesity-conditioned effects and not direct effects of the genetic variants on the metabolic parameters. Further studies, including more candidate genes and other populations, are needed in order to con®rm these results. As the combination of G and P alleles is here speci®cally linked to glycaemia and hypertriglyceridaemia when obesity progresses, it is of interest to analyse the effect of each polymorphism not only taken independently but in combination with each other.
In conclusion, our data support the idea that alleles of speci®c genes (UCP1, LPL and b 3 ± AR) might play a role in the development of metabolic complications of obesity and have possibly additive effects when combined with each other (as in the case of UCP1 and LPL).
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